PepGen Inc.

PEPG

US7133171055

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
14.2 ^USD	-2.00%		+19.03%	+108.82%

Mar. 13	PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	MT
Mar. 13	PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations	DJ

PepGen Inc.(NasdaqGS:PEPG) dropped from Russell 2000 Value-Defensive Index

June 23, 2023 at 12:00 am EDT

Latest news about PepGen Inc.

PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	Mar. 13	MT
PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations	Mar. 13	DJ
Wedbush Trims PepGen's PT to $20 From $21, Incorporates Offering, Adjusts Share Count Assumptions; Maintains Outperform Rating	Mar. 07	MT
Transcript : PepGen Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
PepGen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 06	CI
PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	Mar. 04	CI
PepGen Says FDA Grants Fast Track Designation to Potential Myotonic Dystrophy Type 1 Treatment	Feb. 20	MT
PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	Feb. 20	CI
Mary Beth DeLena Joins PepGen as General Counsel and Secretary	Jan. 17	CI
Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping	Jan. 08	CI
Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1	Dec. 18	CI
PepGen Inc.(NasdaqGS:PEPG) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors	Nov. 15	CI
Wedbush Trims PepGen's PT to $21 From $22, Says Q3 Results Largely Uneventful; Keeps Outperform Rating	Nov. 09	MT
PepGen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
PepGen Says FDA Lifted Clinical Hold on Application to Begin Myotonic Dystrophy Type 1 Phase 1 Study	23-10-12	MT
FDA Lifts Hold on PepGen's New Drug Application for Dystrophy Treatment	23-10-12	DJ
PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1	23-10-12	CI
PepGen Inc.(NasdaqGS:PEPG) dropped from S&P Global BMI Index	23-09-18	CI
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences	23-09-06	CI
PepGen Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
PepGen Inc.(NasdaqGS:PEPG) dropped from Russell 2000 Value-Defensive Index	23-06-23	CI
PepGen Inc.(NasdaqGS:PEPG) dropped from Russell 2000 Growth-Defensive Index	23-06-23	CI
PepGen Inc.(NasdaqGS:PEPG) dropped from Russell 2000 Defensive Index	23-06-23	CI

PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Companyâs pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.2 USD

Average target price

21.6 USD

Spread / Average Target

+52.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PEPGEN INC.	+108.82%	460M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research

PepGen Inc.

Equities

PEPG

US7133171055

Biotechnology & Medical Research

PepGen Inc.(NasdaqGS:PEPG) dropped from Russell 2000 Value-Defensive Index

Latest news about PepGen Inc.

Chart PepGen Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research